GST-HG131,99.94%
产品编号:Bellancom-134790| CAS NO:2270215-69-3| 分子式:C23H29NO7| 分子量:431.48
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
GST-HG131
产品介绍 | GST-HG131 是一种特异性的乙肝病毒 (HBV) 表面抗原抑制剂,属于二氢苯并吡哆醛 (DBP) 类化合物。GST-HG131 抑制 HBsAg 和 HBeAg 的特异性和效力很强 (EC50=28.2 nM, 16.0 nM)。GST-HG131 还具有良好的动物安全性。 | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | GST-HG131 is a specific inbihitor of hepatitis B virus (HBV) surface antigen, belongs to dihydrobenzopyridooxazepine (DBP) series. GST-HG131 exhibits excellent and specific HBV antigens inhibition with EC50 of 28.2 nM (HBsAg) and 16.0 nM (HBeAg), respectively, but also it is safety for animal. | ||||||||||||||||||||||||||||
体外研究 |
GST-HG131 shows moderate permeability in Caco-2 assay, low rat and human plasma protein binding, low clearance in liver microsomal stability assays. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis
|
||||||||||||||||||||||||||||
体内研究 (In Vivo) |
GST-HG131 exhibits low clearance, moderate plasma half-life (T1/2), high plasma exposure (Cmax and AUC) and oral bioavailability.
西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||||||||||||||
体内研究 |
GST-HG131 exhibits low clearance, moderate plasma half-life (T1/2), high plasma exposure (Cmax and AUC) and oral bioavailability.
西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||||||||||||||
体内研究 |
GST-HG131 exhibits low clearance, moderate plasma half-life (T1/2), high plasma exposure (Cmax and AUC) and oral bioavailability.
西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||||||||||||||
性状 | Solid | ||||||||||||||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 100 mg/mL (231.76 mM; ultrasonic and warming and heat to 60°C) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||||||||||||
储存方式 |
| ||||||||||||||||||||||||||||
参考文献 |